Navigation Links
Victhom and Otto Bock sign partnership agreement to establish joint venture for Neurobionix activities
Date:4/30/2009

of capital converted, and the consolidation of its common shares on a 10 for 1 basis. The transfer of the assets of the Neurobionix division will also be implemented by way of the plan of arrangement.

Victhom expects to hold separate debenture holder and shareholder meetings in early June to obtain certain required approvals for the above-mentioned plan of arrangement as well as the creation of the JV. Further details on the plan of arrangement and the transaction with Otto Bock will be provided in an information management circular expected to be distributed to its shareholders and debenture holders by mid-May. In addition to debenture holders and shareholders approvals, implementation of the JV transaction and the plan of arrangement is subject to approval by the Court under the Canada Business Corporations Act and receipt of all necessary regulatory and stock exchange approvals.

The principal debenture holders and shareholders have executed support agreements with Victhom and Otto Bock whereby they agreed to vote in favor of the transaction with Otto Bock and the concurrent implementation of the plan of arrangement.

The board of directors of Victhom is recommending to both the shareholders and the debenture holders to support the transaction as it will provide Victhom with the opportunity to develop its technologies under new parameters providing a stronger financial base for the future.

Mr. Normand Rivard, Acting President and CFO of Victhom, said: "We are tremendously enthusiastic with the prospect of teaming up with Otto Bock, the world leader in the field of mobility. This partnership is designed to exploit the great potential of our unique Neurobionix technology platform incorporated in the Neurostep. The combination of our technology know-how and Otto Bock's worldwide market knowledge will give us a tremendous edge in bringing this much needed solution to gait patients throughout the world. The interest from Otto Bock is a v
'/>"/>

SOURCE VICTHOM HUMAN BIONICS INC.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related biology technology :

1. Victhom announces the filing of a patent application to address sudden unexplained death in epilepsy (SUDEP)
2. Victhom Human Bionics Receives CE Mark for the Neurostep(TM) System, the Worlds First Fully Implantable Closed-Loop Neuromodulation Therapy for Treatment of Foot Drop
3. Victhom Human Bionics Neurobionix Division receives ISO 13485:2003 Certification for its Design Control System
4. Victhom announces the completion of the second phase of the apnea therapy development
5. Victhom Announces Launch of Enhanced Company Website
6. Victhom to Participate in the OneMedPlace Finance Forum
7. Victhom announces promising results on the proof of concept for its unique closed-loop neuromodulation system
8. DATATRAK International, Inc. Forms Strategic Partnership with Inclinix, Inc.
9. ImQuest BioSciences and Arisyn Therapeutics Announce Strategic Partnership to Develop Infectious Disease and Cancer Drugs
10. E&K Scientific Announces Partnership with Sciformatix
11. PRA International Presents Key Budgeting Strategies at 18th Annual CRO Partnerships Conference

Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/24/2009)...ewswire-FirstCall/ -- Shire plc (LSE: SHP,NASDAQ:...company, today,announced that it has submitted a M...ase alfa, the company,s enzyme replacement therapy...r disease. This is the third marketing,application...ith previous,submissions in the United States and ...
(Date:11/24/2009)...24 Genomic Health, Inc. ... Genomic Health,s Executive Chairman, will present...erence in New York City on Tuesday, December 1, 20... subsequently archived webcast of the presentation...Health,s website at http://investor.genomichealth...
(Date:11/24/2009)...s Customers with Partners Validated to Process and...ts , Ottawa, ON (PRWEB) N...der of products for biological sample collection, ... new global partner program. The program offers si...ommunity and is designed to help partners scale an...
(Date:11/24/2009)...ire-FirstCall/ -- Cell Therapeutics, Inc. (CTI) (N...e 21st Annual Piper Jaffray Health Care Conference...at the New York Palace Hotel. ,, CTI will pre...Time in Holmes 1 (4th Floor). A live audio webcast...elltherapeutics.com , and it will also be availabl...
Breaking Biology Technology:Shire Submits European Marketing Authorization Application (MAA) for velaglucerase alfa for the Treatment of Type 1 Gaucher Disease 2Shire Submits European Marketing Authorization Application (MAA) for velaglucerase alfa for the Treatment of Type 1 Gaucher Disease 3Shire Submits European Marketing Authorization Application (MAA) for velaglucerase alfa for the Treatment of Type 1 Gaucher Disease 4Genomic Health to Present at Piper Jaffray Health Care Conference 2DNA Genotek Launches Global Partner Program 2DNA Genotek Launches Global Partner Program 3
...EXTON, Pa., Sept. 12 Kensey Nash Corporation,(Nas...al West Coast Emerging,Growth Institutional Invest...day, September 25, 2007. Joseph W. Kaufmann, Kens...y,s presentation, beginning at approximately 7:55 ...lable on the company,s website,( http://www.kensey...
...National One-Day Meetings Scheduled for London, Pa...and Princeton, NJ, PHILADELPHIA, Sept. 12 Thomso...: TOC ; TSX: TOC) and leading provider,of informa...ess,communities, announced today that it will be h...tion, regulatory affairs, competitive intelligence...
...Over 20 Targanta-Related Posters and Presentations... Targanta Therapeutics,Corporation today announced...biotic candidate, oritavancin, and its antibiotic ...l Interscience Conference on,Antimicrobial Agents ...September 17-20, 2007. Thomas Parr, Ph.D., Chief ...
Other Biology Technology:Kensey Nash to Present at the Sidoti Sixth Annual West Coast Emerging Growth Institutional Investor Forum Conference 2Thomson Scientific to Host Pharmaceutical Vision - A User's Conference for Information, Regulatory Affairs, Competitive Intelligence and Biotechnology Professionals 2Targanta Therapeutics to Have Significant Presence at 47th Annual ICAAC Meeting 2Targanta Therapeutics to Have Significant Presence at 47th Annual ICAAC Meeting 3Targanta Therapeutics to Have Significant Presence at 47th Annual ICAAC Meeting 4Targanta Therapeutics to Have Significant Presence at 47th Annual ICAAC Meeting 5Targanta Therapeutics to Have Significant Presence at 47th Annual ICAAC Meeting 6Targanta Therapeutics to Have Significant Presence at 47th Annual ICAAC Meeting 7
(Date:11/26/2009)... Prized for their impressive antlers, red deer hav...ns. But a deer,s antlers are much more than decora...ether when duelling. John Currey, from The Univers...cal properties of bone for over half a century and...s of antler through a long-standing collaboration ...
(Date:11/26/2009)..., Heidelberg, 27 November 2009 What are the ba...ts required to produce a cell that can survive on ...a cell, and understand how an entire organism func...tions that scientists in a partnership between the...eidelberg, Germany, and the Centre de Regulacio Ge...
(Date:11/25/2009)... Athens, Ga. Bacteria don,t have easy lives. In a...he bugs, they have natural enemies called bacterio...th every two days. , Still, bacteria and anothe...scovered in extreme environments such as deep-sea ...rt because they have a built-in defense system tha...
Breaking Biology News(10 mins):Tough yet stiff deer antler is materials scientist's dream 2First-ever blueprint of a minimal cell is more complex than expected 2First-ever blueprint of a minimal cell is more complex than expected 3Researchers discover biological basis of 'bacterial immune system' 2Researchers discover biological basis of 'bacterial immune system' 3AccuVein Signs Multiple Country Distribution Agreement in Europe for Vein Illumination Device 5555 1AccuVein Signs Multiple Country Distribution Agreement in Europe for Vein Illumination Device 5555 2National Foundation for Infectious Diseases 28NFID 29 Survey 3A Parents More Flu Aware and More Likely to Get Kids Vaccinated 5552 1National Foundation for Infectious Diseases 28NFID 29 Survey 3A Parents More Flu Aware and More Likely to Get Kids Vaccinated 5552 2National Foundation for Infectious Diseases 28NFID 29 Survey 3A Parents More Flu Aware and More Likely to Get Kids Vaccinated 5552 3National Foundation for Infectious Diseases 28NFID 29 Survey 3A Parents More Flu Aware and More Likely to Get Kids Vaccinated 5552 4DigitalPersona Announces Windows 7 Support for Its Enterprise Developer and Consumer Products 10411 1DigitalPersona Announces Windows 7 Support for Its Enterprise Developer and Consumer Products 10411 2DigitalPersona Announces Windows 7 Support for Its Enterprise Developer and Consumer Products 10411 3
... treats this holiday season? Soon, your cell phone...utine and keep the pounds off over winter months, .... , Researchers at the University of Washington a...ons, dubbed UbiFit and UbiGreen, to automatically ...ams display motivational pictures on the phone,s b...
...gricultural research will convene more than 700 le...kers and donor representatives in Maputo, Mozambiq...aches for meeting the food needs of the poor in Af...stem to its coreclimate change, skyrocketing food ...de financial crisis. In just the past three years,...
... 2008Biotech scientists increasingly are applying ...tter understand the effects of novel drug candidat... Engineering & Biotechnology News ( GEN ). They a...pound,s mechanism of action and eventually develop...o the November 15 issue of GEN . ( http://www.gen...
Other Biology News:Track your fitness, environmental impact with new cell phone applications 2Track your fitness, environmental impact with new cell phone applications 3Major conference on food Dec. 1-2, 2008 2
Mouse Anti-Human QPRT Monoclonal Antibody, Unconjugated, Clone 5D11 from ABR-Affinity BioReagents
BD FACSArray bioanalyzer from BD Biosciences - Immunocytometry Systems
Agarose, Type C from Calbiochem
Chicken Anti-Human QPRT Polyclonal Antibody, Unconjugated from ProSci, Inc
Biology Products: